Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women

PHASE4CompletedINTERVENTIONAL
Enrollment

86

Participants

Timeline

Start Date

April 8, 2024

Primary Completion Date

October 22, 2024

Study Completion Date

October 31, 2024

Conditions
Lower Urinary Tract SymptomsFemale Genitourinary DiseaseUrinary Stress IncontinenceUrinary Urge IncontinenceNocturiaQuality of LifeVoiding DisordersVagina AtrophyUrethral AtrophyOveractive BladderOveractive Bladder SyndromeBladder, Overactive
Interventions
DRUG

vaginal 17 beta-estradiol

"* Femiest® Haupt Pharma Munster GMBH, Muenster, Germany~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."

DRUG

Placebo

"* Placebo is produced by Chulalongkorn University Drug and Health Products Innovation \& Promotion Center.~* The assigned dosage will be one vaginal tablet daily for two weeks then one vaginal tablet twice a week for 10 weeks."

BEHAVIORAL

Behavioral modifications

Behavioral modifications for women with storage symptoms of lower urinary tract symptoms (LUTS) involve strategies such as regulating fluid intake, avoiding bladder irritants, practicing bladder training techniques (scheduled and delayed voiding), performing pelvic floor muscle exercises, managing weight, increasing dietary fiber, maintaining a bladder diary, setting a regular voiding schedule, utilizing stress management techniques, and educating patients about LUTS.

Trial Locations (1)

10400

Faculty of Medicine Ramathibodi Hospital, Mahidol University, Ratchathewi

All Listed Sponsors
lead

Mahidol University

OTHER

NCT06508944 - Efficacy of Vaginal 17β-Estradiol on the Urinary Storage Symptoms in Postmenopausal Women | Biotech Hunter | Biotech Hunter